Tenaya Therapeutics (NASDAQ:TNYA) Releases Quarterly Earnings Results

Tenaya Therapeutics (NASDAQ:TNYA) released its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02, FiscalAI reports. The business had revenue of $1.70 million during the quarter, compared to analyst estimates of $0.80 million.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock traded up $0.03 during midday trading on Friday, reaching $0.35. 1,425,568 shares of the company were exchanged, compared to its average volume of 3,465,795. The firm’s 50-day simple moving average is $0.55 and its 200-day simple moving average is $0.70. Tenaya Therapeutics has a 1 year low of $0.30 and a 1 year high of $1.56. The company has a market capitalization of $79.55 million, a price-to-earnings ratio of -0.71 and a beta of 2.88.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on TNYA shares. Wall Street Zen upgraded Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.